RecruitingPhase 1/2

AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)

United States190 participantsStarted 2026-01-09

Plain-language summary

This is a multi-center, open-label Phase 1/2 trial evaluating the safety and efficacy of AB-3028 in subjects with metastatic castration resistant prostate cancer (mCRPC).

Who can participate

Age range18 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. At least 18 years of age at time of signing informed consent form.
✓. Histologically confirmed adenocarcinoma of the prostate, meeting all of the following criteria:
✓. Prior prostate cancer treatment with at least 1 novel androgen receptor pathway inhibitor (ARPI) therapy.
✓. Adequate organ functions.

Exclusion criteria

✕. Any prior systemic therapy for CRPC within 14 days prior to scheduled protocol required leukapheresis.
✕. Central nervous system (CNS) metastatic disease, leptomeningeal disease, or cord compression.
✕. Unwillingness to participate in an extended safety monitoring period.

What they're measuring

Safety and tolerability of AB-3028

Timeframe: From AB-3028 infusion up to 24 months post-infusion

Trial details

NCT IDNCT07285694

SponsorArsenal Biosciences, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2029-05

Contact for this trial

Arsenal Biosciences, Inc.

650-446-4874 clinicaltrials@arsenalbio.com

View on ClinicalTrials.gov More Metastatic Castration Resistant Prostate Cancer (mCRPC) trials